|
|
|
|
Vol. 63, Issue 2, 456-462, February 2003
PET Centre, Centre for Addiction and Mental Health, Toronto,
Ontario, Canada (W.S., N.G., S.K.); and Departments of Psychiatry
(N.G., S.K.) and Pharmacology (W.S., F.K., P.S.), University of
Toronto, Ontario, Canada
Competition with endogenous dopamine (DA) is usually invoked to explain
changes in [11C]raclopride binding observed after
amphetamine administration in animals and humans. This account has
recently been questioned because a number of inconsistencies have been
reported that contradict it. In the present study, we investigated
whether the decrease in [3H]raclopride binding observed
in the rat striatum after an amphetamine challenge reflects true
competition with endogenous DA or agonist-mediated internalization of
D2-receptors. We found that the amphetamine-induced decrease in [3H]raclopride binding is caused by a
decrease in D2-receptor density (Bmax) with no change in affinity
(Kd). In contrast, in the same tissue,
neither the Bmax nor the
Kd were affected when measured with
[3H]spiperone. Challenge with amphetamine not only
decreased the number of D2-receptors but also eliminated
the proportion (22%) of receptors usually in the high-affinity state.
The addition of Gpp(NH)p had no effect on
Bmax, suggesting that these receptors were
not just noncompetitively bound with dopamine at the cell-surface. Subcellular fractionation studies showed that amphetamine treatment led
to a decrease in radioligand binding in the cell-surface fraction for
both [3H]raclopride and [3H]spiperone;
however, in the case of [3H]spiperone, this was
accompanied by a compensatory increase in binding in the intracellular
compartment, whereas no increase was seen with
[3H]raclopride. These data suggest that amphetamine
releases dopamine, which binds to the high-affinity state of the
D2-receptor, leading to its sequestration in some
intracellular compartment; in this compartment, sequestered receptors
are inaccessible to [3H]raclopride binding but can still
be bound by [3H]spiperone.
This article has been cited by other articles:
![]() |
Q. Guo, M. Brady, and R. N. Gunn A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development J. Nucl. Med., October 1, 2009; 50(10): 1715 - 1723. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Leriche, T. Bjorklund, N. Breysse, L. Besret, M.-C. Gregoire, T. Carlsson, F. Dolle, R. J. Mandel, N. Deglon, P. Hantraye, et al. Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy J. Neurosci., February 4, 2009; 29(5): 1544 - 1553. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. den Boer, A.A.T. S. Reinders, and G. Glas Special Section: On Looking Inward: Revisiting the Role of Introspection in Neuroscientific and Psychiatric Research Theory Psychology, June 1, 2008; 18(3): 380 - 403. [Abstract] [PDF] |
||||
![]() |
C. H. So, G. Varghese, K. J. Curley, M. M. C. Kong, M. Alijaniaram, X. Ji, T. Nguyen, B. F. O'Dowd, and S. R. George D1 and D2 Dopamine Receptors Form Heterooligomers and Cointernalize after Selective Activation of Either Receptor Mol. Pharmacol., September 1, 2005; 68(3): 568 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. de la Fuente-Fernandez, V. Sossi, Z. Huang, S. Furtado, J.-Q. Lu, D. B. Calne, T. J. Ruth, and A. J. Stoessl Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain, December 1, 2004; 127(12): 2747 - 2754. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Zald, I. Boileau, W. El-Dearedy, R. Gunn, F. McGlone, G. S. Dichter, and A. Dagher Dopamine Transmission in the Human Striatum during Monetary Reward Tasks J. Neurosci., April 28, 2004; 24(17): 4105 - 4112. [Abstract] [Full Text] [PDF] |
||||